Phase II study of combination chemotherapy with cisplatin / pemetrexed / bevacizumab in patients with relapsed nonsquamous non-small cell lung cancer

Phase II study of combination chemotherapy with cisplatin / pemetrexed / bevacizumab in patients with relapsed nonsquamous non-small cell lung cancer - SMU Th-R1

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014291

Enrollment

Registered

2014-07-01

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed nonsquamous non-small cell lung cancer

Interventions

isplatin(CDDP)/pemetrexed(PEM)/bevacizumab(BEV)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with relapsed nonsquomouse non-small cell lung cancer 2. Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1 3. one or more sites of measurable disease [per Response Evaluation Criteria in Solid Tumours (RECIST) version 1],

Exclusion criteria

Exclusion criteria: nervous system metastasis haemoptysis

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Response rate, Disease control rate, Overall survival, Toxicity, Disease failure interval	—

Countries

Japan

Contacts

Public ContactHisashi Saji

St. Marianna University School of Medicine Chest Surgery

saji-q@ya2.so-net.ne.jp+81-44-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026